Medical Research Future Fund: Cardiovascular Health Mission Implementation Plan

Objectives

The Cardiovascular Health Mission is a Medical Research Future Fund investment framework intended to improve cardiovascular health and stroke outcomes for Australians through research, translation and collaboration, while reducing inequities affecting Aboriginal and/or Torres Strait Islander people.[1][2]It directs activity across short-, medium- and long-term priorities towards potentially transformative improvements in prevention, acute care, recovery and survivorship.[3][4]

• Reduce the number of Australians affected by heart disease and stroke by improving understanding of cardiovascular risk, biological mechanisms and interactions with other chronic diseases.[1][5]
• Develop and implement improved diagnostic markers, risk-prediction methods, early-detection approaches and nationally applicable preventive care.[5][6]
• Improve acute cardiovascular and stroke outcomes through evidence-based diagnosis, clinical pathways, time-dependent event management, tailored prevention and integrated models of care.[1][7]
• Advance novel drugs, devices, technologies and models of care, and support their adoption in clinical practice and commercial development.[1][8]
• Improve recovery, rehabilitation and survivorship through personalised lifelong care, routine monitoring, adherence support, accessible rehabilitation and new recovery treatments.[1][9][10]
• Reduce disparities in cardiovascular and stroke outcomes, particularly by supporting culturally secure, co-designed prevention, treatment and recovery approaches for Aboriginal and/or Torres Strait Islander people.[6][2][10]
• Establish diabetes and cardiovascular disease research centres, investigate interactions between these conditions, and accelerate therapeutics and device development.[5][3]
• Assess the return on investment and health-economic implications of research and implementation.[2]

Implementation

Implementation combines competitive research funding, nationally coordinated data and research infrastructure, cross-sector partnerships, consumer participation and translation into health services.[3][5][2]The Mission has an investment envelope of 220 million dollars over 10 years through the Medical Research Future Fund, including a 47 million dollar Targeted Translation Research Accelerator programme over four years for diabetes and cardiovascular disease research.[1][3]

• Use transparent, predictable investment and competitive processes to support exploratory research, strategic programmes, research centres, partnership projects, early-stage therapeutic and device targets, and commissioned research.[1][5]
• Apply the Targeted Translation Research Accelerator to establish competitive diabetes and cardiovascular research centres, investigate disease interactions and advance promising drugs and devices towards commercialisation.[3][5]
• Coordinate funded projects nationally, leverage core capabilities, avoid duplication and align research activity with health-system priorities and continuous quality improvement.[3]
• Build large-scale platforms linking national and state datasets, primary-care information, hospital registries, electronic health records, biobanks, imaging resources and online bioresources.[5][2]
• Use near real-time data platforms, virtual registries, clinical trial networks, clinical software and performance dashboards to support embedded trials, decision support, quality improvement and monitoring of best care and outcomes.[2][7]
• Engage health services, universities, government departments, industry, private health insurers, research alliances, clinical trial networks, professional bodies, consumer organisations, foundations and international partners.[5][6]
• Embed clinical trial networks in Australian Health Research Translation Centre networks and in health research and primary-care networks, while supporting access to research infrastructure and phase 1 device networks.[8][2]
• Co-design research with consumers, end users and Aboriginal and/or Torres Strait Islander people, including in leadership roles, and use culturally secure methods to improve access, engagement and adherence.[3][9]
• Develop workforce capability in bioinformatics, clinical and large-scale data analysis, data management and interpretation, while creating training and career-development opportunities for early career researchers.[3][10]
• Promote intellectual property development, biotechnology investment, implementation software, commercialisation and partnerships with pharmaceutical and medical technology companies.[2][8][4]
• Collaborate with related Medical Research Future Fund initiatives, including the Genomics Health Futures Mission, Million Minds Mental Health Research Mission and Indigenous Health Research Fund.[5][6]
• Evaluate focus-area outcomes according to benefits for Australian patients and progress towards Mission objectives, using the Medical Research Future Fund Monitoring, Evaluation and Learning Strategy.[1][3]
• Review the Mission and funded grants after three years of disbursements and use findings to revise investment priorities or identify new priorities.[3]
• Monitor national implementation of discoveries, risk assessments, preventive care, acute-care pathways, rehabilitation access, inequalities, consumer feedback, policy uptake and health, economic and social value.[2][7][8][9]
• Undertake economic evaluations and impact assessments of prevention pathways, innovations and implementation.[6][2]

Detailed indicator definitions, numerical targets, reporting schedules and a single Mission-specific governance or accountability structure are not specified in the supplied material.[3][5][6][4][10]

Monitoring & Evaluation

Monitoring and evaluation combine mission-level review with measurement of research translation, care quality, equity, recovery and economic impact. The Medical Research Future Fund framework requires evaluation to be independent, impartial, transparent and responsive to consumers and stakeholders, while the mission will review funded activity after three years of disbursements.[3]

• Evaluate outcomes in each priority area according to benefits for Australian patients, intended outcomes and progress towards mission objectives.[1]
• Review the mission and funded grants after three years of disbursements, and use findings to modify investment priorities or identify new priorities where appropriate.[3]
• Monitor the national availability and implementation of discoveries, biomarkers, diagnostic and prognostic tools, clinical pathways, preventive approaches, treatments, interventions and devices.[2][8]
• Track the proportion of eligible people receiving cardiovascular and stroke risk assessments and the proportion of at-risk people receiving best-practice preventive care.[2][7]
• Assess adoption, adherence and effects on inequalities when evaluating diagnostic markers, risk-prediction methods, clinical pathways and preventive interventions.[5][6]
• Measure access to care, uptake of new evidence in acute-care guidelines or policy, provision of best-practice acute care, and performance against best-care and best-outcome dashboards.[7][8]
• Assess reductions in inequalities in cardiovascular disease, stroke and rehabilitation outcomes, particularly for Aboriginal and/or Torres Strait Islander people and other at-risk populations.[2][8][11]
• Measure whether more people access effective rehabilitation after cardiovascular disease and stroke, alongside participation, treatment adherence and survivor health outcomes.[9][10][11]
• Use national and state data linkage, primary-care data, clinical registries, cohorts, biobanks, clinical trials, near real-time platforms and electronic health records to strengthen monitoring, embedded research and quality improvement.[5][6][2][7]
• Use consumer feedback, health-system monitoring, policy change and impact-measurement data platforms to identify ongoing gaps and assess health, economic and social value.[8][9]
• Undertake economic evaluations, return-on-investment assessments and wider health-economic impact assessments of prevention pathways, innovations, research and implementation.[6][2]

The supplied material does not specify numerical targets, indicator definitions, a routine reporting schedule, a dedicated surveillance system or a named accountability body beyond the overarching Medical Research Future Fund monitoring, evaluation and learning framework.[3][5][6][4][10][11]

Costing & Financing

The principal quantified commitment is an Australian dollars 220 million investment over 10 years for the Cardiovascular Health Mission through the Medical Research Future Fund. A further Australian dollars 47 million Targeted Translation Research Accelerator programme over four years supports diabetes and cardiovascular disease prevention, early detection and treatment research.[1][3]

• Fund the mission through the Medical Research Future Fund investment envelope, directing resources across short-, medium- and long-term priorities.[1][3]
• Support competitive research centres, projects and partnership projects through the Targeted Translation Research Accelerator, including work on diabetes and cardiovascular disease interactions and drug and device development.[3][5]
• Use competitive investment, co-funded grants, partnership projects, leveraged funding and sustainable commercial and international partnerships to mobilise further research resources.[5][6]
• Seek matched funding where feasible through implementation partners including the Heart Foundation and Stroke Foundation.[7]
• Engage government departments, health services, universities, industry, private health insurers, research alliances, clinical trials networks, pharmaceutical and medical technology companies, philanthropic organisations and venture capitalists as potential co-investors or resource partners.[5][6][4][10]
• Invest in research infrastructure, data platforms, clinical trials, biotechnology, commercialisation, workforce development and researcher career sustainability.[8][9][10]
• Assess return on investment and health-economic implications as part of research prioritisation and implementation evaluation.[2]

Beyond the two stated programme envelopes, the material does not specify itemised allocations, expenditure profiles, funding gaps, financing targets, unit costs, economic assumptions or quantified commitments from partner organisations.[3][5][6][7][8][9][4][10]